Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMETEO-HG
2024-516561-37-01Phase 3Authorised
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and prediabetes comparing Pioglitazone monotherapy, Metformin monotherapy and Pioglitazone + metformin combination (3 arms). Primary endpoint: Significant decrease in intrahepatic fat without fibrosis progression. Planned start Dec 2024; status: authorised.
02
Drugs
pioglitazonemetformin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)prediabetes
Beyond the preview
Go deeper on 2024-516561-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516561-37-01.